glg_pharma_logo-02-04-182-1
  • English - United States
  • Deutsch – Liechtenstein
  • Español
  • Français
  • Italiano - Italia
  • Português
  • 日本語 - 日本
English - United States
glg_pharma_logo-02-04-182-1

The GLG Pharma STAT Blog

STAT3, Cancer and Genetics - GLG Pharma

GLG Pharma STAT 3 Blog

GLG Pharma Announces Presentation at Upcoming AACR, the Annual Cancer Research Meeting 2015 April 18-22, 2015

GLG Pharma at Rare Disease Day Tallahassee Florida!

Why Work on Treatment or Cures for Rare Diseases?

WIIFM?

SEC Reviews Accredited Investor Requirements

Why Invest in Early Stage Drug Development for Rare Diseases?

GLG Pharma Attending Faster Cures Partnering Nov. 16-18 NYC

The Alpha-1 Antitrypsin Deficiency Walk!

Why are STAT3 Inhibitors Important in Cancer Therapy?

Who is Your Patient Advocate?

The Entrepreneur's Real Valley of Death

The New Way to Fund Biotech/Pharma/Lifescience Startups?

Funding News! CB Insights 'The Bull is in Full Swing'!

GLG Focused on Polycystic Kidney Disease and Alpha-1 Tryptase and HCC

Why is GLG Pharma Different?

GLG-302 Selected by NCI for Funding in Cancer Prevent Program

Startup Funds Still Available! Matching Grant for Investment in Cancer Drug Development.

All posts

STAT 3 publications are numerous and we hope that the following links will help you better understand it's importance in cancer cell metabolism and cancer cell death. Inhibiting STAT 3 is an important mechanism for encouraging cancer cell death. Using STAT 3 inhibitors with other traditional cancer chemotherapy should help improve patient outcomes. Linking a diagnostic with a STAT 3 inhibitor will also help reduce patient side effects as well as potentially improve patient outcomes.

Latest Posts

Browse by Tag

  • accredited investor (2)
  • accredited investors (2)
  • Alpha-1 (5)
  • Alpha-1 Antitry (2)
  • Alpha-1 Antitrypsin deficiency (1)
  • angel investor (2)
  • angel investors (2)
  • Cancer (8)
  • cancer diagnosis (6)
  • cancer prevention (3)
  • Cancer Stem Cells (3)
  • Cancer Therapy (3)
  • Chemotherapy (2)
  • GLG (2)
  • GLG Pharma (13)
  • jobs act (1)
  • PKD (2)
  • Polycystic Kidney Disease (3)
  • Rare Disease (1)
  • Rare Diseases (3)
  • sec (1)
  • STAT (6)
  • STAT 3 inhibitors (6)
  • STAT3 (15)
  • STAT3 cancer (7)
  • STAT3 inhibitors (11)
  • STAT3 mechanism (1)
  • WIIFM (1)

Links

Mayo Clinic

Moffitt Cancer Center

Dana-Farber

Connect With Us

glg_pharma_logo-02-04-182-1
Follow us on Facebook Follow us on LinkedIn Follow us on Twitter Follow us on Instagram
  • Home
  • About
  • Blog
  • News
  • Contact
  • Products
  • Services

Get News and Updates about GLG

Copyright © 2025, GLG Pharma
Privacy Policy | Terms of Use